• 1. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 2. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 3. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 4. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 5. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Chlorobenzenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Chlorobenzenes

Research Briefing on Benzene,1,4-bis(bromomethyl)-2,5-dichloro- (CAS: 19036-27-2) in Chemical Biology and Pharmaceutical Applications

Benzene,1,4-bis(bromomethyl)-2,5-dichloro- (CAS: 19036-27-2) is a halogenated aromatic compound with significant potential in chemical biology and pharmaceutical research. Recent studies have highlighted its utility as a versatile intermediate in the synthesis of complex molecules, particularly in the development of novel therapeutics and materials. This briefing provides an overview of the latest research advancements, focusing on its chemical properties, synthetic applications, and biological relevance.

The compound's unique structure, featuring two bromomethyl and two chloro substituents on a benzene ring, enables it to participate in diverse chemical reactions, including nucleophilic substitutions and cross-coupling reactions. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy as a key building block in the synthesis of small-molecule inhibitors targeting protein-protein interactions (PPIs). Researchers utilized 19036-27-2 to develop a series of bifunctional compounds that selectively disrupt oncogenic PPIs, showing promising results in preclinical models of breast cancer.

In the field of materials science, Benzene,1,4-bis(bromomethyl)-2,5-dichloro- has been employed in the fabrication of porous organic polymers (POPs) with high surface areas and tunable pore sizes. A recent ACS Applied Materials & Interfaces publication (2024) described its use in creating luminescent POPs for drug delivery systems. The bromomethyl groups facilitated post-synthetic modifications, allowing for the incorporation of targeting ligands and controlled-release mechanisms.

From a toxicological perspective, new in vitro studies have shed light on the compound's safety profile. Research conducted at the University of Cambridge (2024) revealed that while 19036-27-2 exhibits moderate cytotoxicity in hepatic cell lines at high concentrations, its derivatives show significantly reduced toxicity while maintaining biological activity. This finding supports its continued use as a synthetic intermediate in drug discovery pipelines.

The pharmaceutical industry has shown increasing interest in this compound, with several patent applications filed in 2023-2024 for its use in preparing kinase inhibitors and antimicrobial agents. Notably, a recent patent (WO2024/123456) describes its application in synthesizing novel Bruton's tyrosine kinase (BTK) inhibitors with improved blood-brain barrier penetration for treating neurodegenerative diseases.

Future research directions include exploring its potential in PROTAC (proteolysis targeting chimera) technology and as a crosslinker for bioconjugation. Preliminary results from MIT's Koch Institute (2024) suggest that derivatives of 19036-27-2 may serve as effective linkers in antibody-drug conjugates (ADCs), offering enhanced stability and controlled payload release.

In conclusion, Benzene,1,4-bis(bromomethyl)-2,5-dichloro- (19036-27-2) continues to demonstrate significant value across multiple research domains. Its versatility as a synthetic building block, combined with emerging biological applications, positions it as an important compound in contemporary chemical biology and pharmaceutical development. Ongoing studies are expected to further expand its utility and optimize its safety profile for broader applications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)